An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin

Numerous patients develop diabetes in response to glucocorticoid therapy. This study explored the efficacy, safety, and preventive potential of the dipeptidyl peptidase-4 inhibitor, linagliptin (TRADJENTA®), i...

https://ift.tt/2P9cBzm